Unity Biotechnology获贝索斯支持，融资1.16亿美元研发抗衰老药物

做的是什么生意

Unity Biotechnology develops drugs that clear senescent cells — aging cells linked to chronic disease — by repurposing apoptosis-inducing drug candidates from cancer research into a standard drug-development pipeline.

启动资金：$116M Series B announced around 2016-10-27, with backing Bloomberg credited to Jeff Bezos.

起因

By late 2016 Unity Biotechnology was, in the description of a detailed commenter on its own funding thread, arguably the most mainstream of the startups targeting the clearance of senescent cells as a rejuvenation therapy — a company characterized by high-profile relationships with noted laboratories, venture groups and big names in the field. The approach rested on research going back decades: senescent cells accumulate with age and, even at about one percent of a tissue, secrete signals that disrupt structure and behavior, while remaining few enough to clear without major disruption.

经过

The company's $116M Series B financing was announced around 2016-10-27, timed with its latest published research on senescent cells in atherosclerosis pathology, a pattern one commenter approvingly noted. Bloomberg's coverage credited the round with backing from Jeff Bezos. The discussion framed Unity as following the standard playbook for a hot drug company — repurposing apoptosis-inducing drug candidates to clear senescent cells — while skeptics argued that senescent cells are an evolved anti-cancer mechanism, so clearing them could trade aging for cancer, and that investors might really be betting on a cancer-adjacent market rather than rejuvenation.

可借鉴之处

当包装成普通药物开发商时，一个未经证实的领域可以像已证实的领域一样融资——Unity的重用管线让顶级投资机构投入1.16亿美元支持衰老细胞科学。